Crossmark

The Health Economics of Genomic Technologies: A Growing Evidence Base on Value

Published Online: 2025-04-28

Published Print: 2025-05

Authors

Buchanan, James https://orcid.org/0000-0003-2528-0638
Goranitis, Ilias

Weymann, Deirdre
License Information

Text and Data Mining valid from 2025-04-28

Version of Record valid from 2025-04-28
More Information

Article History

Accepted: 13 April 2025

First Online: 28 April 2025

Declarations

:

: No funding was received to support the writing of this editorial.

: James Buchanan, Ilias Goranitis and Deirdre Weymann are the Guest Editors of this themed issue of Applied Health Economics and Health Policy. For articles in the themed issue with any of the Guest Editors as co-authors, that/those Guest Editor(s) were not involved in the selection of peer reviewers nor any of the subsequent editorial decisions. James Buchanan reports travel funding from Illumina, Inc. and consulting income from Genomics England. Deirdre Weymann co-directs IMPRINT Research Consulting and has consulted for AstraZeneca, Birota Economics Group, and LHS Labs.

Document is current